Although the previous analysis of the J-CaP registry data provided valuable information on the contemporary treatment of prostate cancer in Japan, the follow-up period was too short to analyse long-term outcomes, including PSA progression-free survival (PSA-PFS). This evidence concerns the gene KLK3 and prostate cancer.